- Oral presentation
- Open Access
Neurocognitive effects of HCV, methamphetamine abuse, and HIV: multiple risks and mechanisms
Annals of General Psychiatry volume 7, Article number: S39 (2008)
HIV-infected individuals are at risk for a spectrum of neurocognitive disorders. Research performed in developed and resource-limited settings indicates that over half of HIV-infected individuals may have neurocognitive impairment of at least mild severity. An important issue complicating the pathogenesis of these disorders is the co-existence of multiple neurotoxic conditions. Two important comorbidities are co-infection with Hepatitis C Virus (HCV) and use of stimulants, such as methamphetamine (MA).
The WHO estimates that 3% of the world's population has been infected with HCV, leaving 170 million chronically infected. HCV co-infects approximately a third of all HIV-infected individuals, 75-90% of HIV-infected intravenous drug users, and nearly 100% of some groups of HIV-infected hemophiliacs. The longer life expectancy of HIV-infected individuals since the advent of combination antiretroviral therapy has highlighted the impact of chronic HCV, which has emerged as a frequent cause of death in HIV-infected people.
A growing body of literature fuels the notion that HCV can injure the brain. First, HCV can infect resident (e.g., astrocytes) and migrating (e.g., macrophages) cells of the central nervous system (CNS). Second, HCV can adapt to neural cells, as evidenced by phylogenetic compartmentalization. Third, the neuropsychological (NP) performance of HCV-infected individuals is more likely to be impaired than that of uninfected individuals. Fourth, magnetic resonance spectroscopy demonstrates that HCV-infected individuals have elevated choline-to-creatine ratios in the basal ganglia and white matter, suggesting inflammation, and reduced N-acetyl aspartate in white matter, suggesting neuronal loss.
Chronic or heavy exposure to MA has also been associated with brain injury. MA may injure the brain by multiple mechanisms including interfering with dopamine metabolism, altering glutamate processing by astrocytes, increasing TNF-alpha expression, and worsening oxidative stress. In HIV-infected individuals, MA may also increase HIV replication.
These and other data support that each of these conditions can lead to brain injury and that their effects may be additive. The high prevalences of these conditions also highlight important public health concerns. For example, the substantial cognitive impairment in these populations may negatively affect their ability to manage complex medical therapy. As a result, their likelihood of recovery - and survival - may be greatly reduced.
About this article
Cite this article
Letendre, S.L. Neurocognitive effects of HCV, methamphetamine abuse, and HIV: multiple risks and mechanisms. Ann Gen Psychiatry 7, S39 (2008). https://doi.org/10.1186/1744-859X-7-S1-S39
- Neurocognitive Impairment
- Neurocognitive Disorder
- Intravenous Drug User
- Longe Life Expectancy